- Home
- FEDU vs GOVX Comparison
FEDU vs GOVX Comparison
Compare FEDU & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEDU
- GOVX
- Stock Information
- Founded
- FEDU 2007
- GOVX 2001
- Country
- FEDU China
- GOVX United States
- Employees
- FEDU N/A
- GOVX N/A
- Industry
- FEDU
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- FEDU
- GOVX Health Care
- Exchange
- FEDU NYSE
- GOVX Nasdaq
- Market Cap
- FEDU 22.1M
- GOVX 23.8M
- IPO Year
- FEDU 2017
- GOVX N/A
- Fundamental
- Price
- FEDU $11.15
- GOVX $2.31
- Analyst Decision
- FEDU
- GOVX Strong Buy
- Analyst Count
- FEDU 0
- GOVX 5
- Target Price
- FEDU N/A
- GOVX $14.20
- AVG Volume (30 Days)
- FEDU 1.3K
- GOVX 721.5K
- Earning Date
- FEDU 12-27-2024
- GOVX 11-12-2024
- Dividend Yield
- FEDU 20.37%
- GOVX N/A
- EPS Growth
- FEDU N/A
- GOVX N/A
- EPS
- FEDU 0.29
- GOVX N/A
- Revenue
- FEDU $17,447,877.00
- GOVX $3,090,161.00
- Revenue This Year
- FEDU N/A
- GOVX N/A
- Revenue Next Year
- FEDU N/A
- GOVX $159.12
- P/E Ratio
- FEDU $38.00
- GOVX N/A
- Revenue Growth
- FEDU 266.63
- GOVX N/A
- 52 Week Low
- FEDU $7.41
- GOVX $1.09
- 52 Week High
- FEDU $22.70
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- FEDU 53.90
- GOVX 44.80
- Support Level
- FEDU $11.00
- GOVX $2.17
- Resistance Level
- FEDU $12.23
- GOVX $2.50
- Average True Range (ATR)
- FEDU 0.43
- GOVX 0.17
- MACD
- FEDU 0.11
- GOVX -0.04
- Stochastic Oscillator
- FEDU 70.44
- GOVX 18.33
About FEDU FOUR SEASONS EDUCATION (CAYMAN) INC SPON ADS EACH REP 10 ORD SHS(R/S)
Four Seasons Education (Cayman) Inc is engaged in the provision of after-school education services for kindergarten, elementary and middle school students. The Company derives its revenue from learning services, tourism services, and learning technology and content solutions. The company is a comprehensive educational enterprise that provides research practice services, educational informatization equipment, high-quality educational resources, and teacher training, as well as a digital publishing business, and continues to expand in educational research and educational informatization.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.